Get Instant Newsletter Alerts to your Mobile Device and Email as soon as the News or Alerts hit the wire.
**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.
Cadrenal Therapeutics Inc is focused on developing a novel therapy with orphan drug indication, tecarfarin, for the prevention of systemic thromboembolism (blood clots) of cardiac origin in patients with end-stage renal disease (on dialysis) and atrial fibrillation (irregular heartbeat) or AFib. Tecarfarin is an anticoagulant designed using a drug design process that targets a different pathway than most commonly prescribed drugs for the treatment of thrombosis and AFib.
| Last: | $7.935 |
|---|---|
| Change Percent: | -0.89% |
| Open: | $7.89 |
| Close: | $8.0064 |
| High: | $8.19 |
| Low: | $7.71 |
| Volume: | 16,372 |
| Last Trade Date Time: | 03/11/2026 12:36:37 pm |
| Market Cap: | $13,584,518 |
|---|---|
| Float: | 1,728,110 |
| Insiders Ownership: | 8.81% |
| Institutions: | 8 |
| Short Percent: | N/A |
| Industry: | Biotechnology & Life Sciences |
| Sector: | Healthcare |
| Website: | https://www.cadrenal.com |
| Country: | US |
| City: | Ponte Vedra |
Get Instant Newsletter Alerts to your Mobile Device and Email as soon as the News or Alerts hit the wire.
**MWN-AI FAQ is based on asking OpenAI questions about Cadrenal Therapeutics Inc. (NASDAQ: CVKD).
Link your X account with Market Wire News to automatically tweet trending stocks news and your portfolio stocks news.
Get instant news alerts to your mobile device as soon as the news hits the wire. Simply add a stock symbol to your portfolio and our service will alert you anytime there is news.
